The US Food and Drug Administration has agreed to extend the expiry date of Johnson & Johnsonās Covid vaccine to six months, pushing it out for the second time as states ādrowningā in jabs struggle to get rid of them.
The Big Pharma firm saidĀ in aĀ statementĀ on Wednesday that the FDA had approved the new expiration date, adding that the decision had beenĀ ābased on data from ongoing stability assessment studies, which have demonstrated the vaccine is stable at six months.ā
The regulator said in aĀ letterĀ to J&J that the extended shelf life would also apply to batches that had previously expired as long as they had been stored at a specified temperature.
FDA extends J&J #covid19 vaccine shelf life again, now to 6 months https://t.co/Hou2D8qQAm pic.twitter.com/bUWp7705ez
— Meg Tirrell (@megtirrell) July 28, 2021
Wednesdayās extension is the second approved for the J&J shot, with the FDAĀ extendingĀ its original three-month life span to four-and-a-half months on June 10. That move came as officials in a number of states warned that their unused doses would expire before the end of June.
Last week, the medical news outlet StatĀ reportedĀ thatĀ āseveral state health departmentsāĀ had recently called on the federal government toĀ āredistribute their supply to other countries,āĀ pointing to fears the doses would soon be rendered useless.
āWeāre drowning in this stuff,āĀ Robert Ator, who heads up Arkansasā vaccine roll-out, said of the stateās stockpile.Ā āItās starting to get a bit silly and we want to make sure weāre being good stewards.ā
Stat observed that waste could be avoided if health officials agreed to extend the vaccinesā shelf lives, but notedĀ āsuch expiration dates can only be extended so far.ā
In New Jersey, Delaware, and Pennsylvania alone, more thanĀ 800,000 J&J dosesĀ were at risk of going to waste as of late June, as health officials struggled to convince residents to receive the jab. Some of the reluctance may stem from an FDA order to halt the J&J roll-out in April to look into potentially serious side effects. While it determined the adverse reactions were highly uncommon, that scare ā as well asĀ others sinceĀ ā may have been enough to turn off some residents for good.
While J&Jās vaccine was highly anticipated due to its single-shot formulation, competitors Pfizer and Moderna largely beat it to the punch, with their own jabs granted emergency approval months before J&Jās. Moreover, the two rival companies have already supplied more than enough doses to vaccinate all eligible Americans, withĀ 150 millionĀ already fully immunized with their two-dose shot, compared to just 13 million for J&Jās vaccine.
Think your friends would be interested? Share this story!